Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12922268 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| Hydrochloric Acid SCHEMBL976093 | 0.99 | KDM4E (0.45) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL974580 | 0.87 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL18308684 | 0.85 | KDM4E (0.48) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL18308683 | 0.85 | KDM4E (0.48) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL12945021 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL18078284 | 0.82 | PIK3CD (0.37) | PIK3CD | |
| SCHEMBL975292 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL975016 | 0.78 | PIK3CD (0.42) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL975148 | 0.78 | PIK3CD (0.56) | KDM4EALDH1A1HPGDHSD17B10GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-04-23 | — | — | US | disclosed |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | INCYTE CORPORATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180362546-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2018-12-20 | — | — | US | disclosed |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2012125629-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125629-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| WO-2011008487-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401280-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | KDM4E 1496/4885ALDH1A1 2549/4885HPGD 1311/4885 |
| US-10428087-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | KDM4E 1496/4885ALDH1A1 2549/4885HPGD 1311/4885 |
| US-20140121222-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KDM4E 1496/4885ALDH1A1 2549/4885HPGD 1311/4885 |
| US-20210253601-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KDM4E 1496/4885ALDH1A1 2549/4885HPGD 1311/4885 |
| US-20140066448-A1 | SUBSTITUTED DIAMINO-PYRIMIDINE AND DIAMINO-PYRIDINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PDPK1, PIK3CD | KDM4E 948/4885ALDH1A1 2187/4885HPGD 1549/4885 |
| US-10829502-B2 | Pyrimidinones as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | KDM4E 1496/4885ALDH1A1 2549/4885HPGD 1311/4885 |
| US-20180362546-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KDM4E 1496/4885ALDH1A1 2549/4885HPGD 1311/4885 |
| US-20200123176-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KDM4E 1496/4885ALDH1A1 2549/4885HPGD 1311/4885 |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KDM4E 1496/4885ALDH1A1 2549/4885HPGD 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.